Abstract
The complete blood count (CBC) is one of the most requested tests by physicians. Mostly realized in conventional hematological analyzers, CBC tests are restricted to centralized laboratories, due to frequent maintenance, size of devices, and expensive costs that these analyzers require. On the other hand, most handheld CBC devices commercially available present high costs and are not liable to calibration or control procedures, which results in poor quality compared to standard hematology instruments. The Hilab system is a small-handed novel hematological platform that uses microscopy and chromatography techniques for blood cells and hematimetric parameters analysis. Combining artificial intelligence, machine learning, and deep learning techniques, provides the main parameters evaluated in the CBC test and four-part differential WBC. For clinical evaluation, accuracy, precision, method comparison, and flagging capabilities of the Hilab System were compared with the Sysmex XE-2100 (Sysmex, Japan) results. Over the entire measuring range, a strong correlation (r > 0.9) between both methodologies was obtained for most parameters evaluated. Also, high accuracy (> 0.85), and adequate precision values were observed. The anticoagulant influence and the sample source (venous and capillary) effect were also evaluated, and no significant differences were observed (p > 0.05). Thus, considering the need for blood count point-of-care tests, especially for quickly patient management, the study indicated that the Hilab system provides fast, accurate, low cost, and robust blood cell analysis for reliable clinical use.
Key points
The Hilab system presents a high correlation with a standardized reference analyzer for all evaluated CBC parameters;
The flagging capabilities of the Hilab system present high accuracy compared to results provided by specialized hematologists.
Competing Interest Statement
M. V. M. Figueredo is the CEO at Hilab; S. Rogal is the CTO at Hilab; A. T. Gasparin is microscopy manager at Hilab; C. I. F. Araujo, M. C. Perussolo, and T. C. S. Jesus are health researchers at Hilab; E. B. Santiago is R&D manager at Hilab; I. L. R. Silva is head of R&D at Hilab; R. G. Souza and F. Z. Teng are R&D researchers at Hilab; E. B. Severo is computer vision engineer at Hilab; V. H. A. Ribeiro is head of A.I at Hilab; M. A. Cardoso and F. D. Silva are A.I researchers at Hilab; C. R. A. Perazzoli is marketing analyst at Hilab; J. S. H. Farias is assistant doctor at Erasto Gaertner Hospital; B. M. M. Almeida is medical director at Hilab.
Funding Statement
This study was supported by research funding from Hi Technologies, to M. F. and S. R.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Research Ethics Committee of the Paranaense League Against Cancer (CAAE number 49961421.3.1001.0098)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For original data and analysis code, please contact alexia.gasparin{at}hilab.com.br.
